Linc AB operates as an investment company, specializing in both private equity and venture capital, with a dedicated focus on the Nordic life science industry. The firm directs its capital toward product-oriented businesses, primarily within the pharmaceutical and medical technology sectors. Linc strategically invests across various development stages, typically engaging in pharmaceutical endeavors during earlier phases, while entering medical technology ventures at more mature points. The company, which successfully completed its initial public offering on Nasdaq Stockholm in May 2021, prefers to secure long-term share ownership in these companies, encompassing both publicly traded and privately held entities. Investments typically range from SEK 25 million to SEK 250 million, often starting with a smaller initial commitment that is then augmented by subsequent, more substantial follow-on investments. Linc acts as an active, long-term owner, providing not just financial backing but also valuable expertise, extensive industry networks, and strategic support to its portfolio companies. The company is headquartered in Stockholm, Sweden.